Someone has alerted Dirk to this study and he has questioned whether or not it relates to the clinical trial currently being conducted by Calimmune.
The slides referred to by MaxM do appear to relate to the current trial but the mice study seems to be research on a different, parallel path. The mice study refers to the treatment using sh1005, sh516 whereas the clinical trial refers to using LVsh5 and a gene for C46. I am not a scientist so does anyone else know if the mouse study is another path that Calimmune may also take to the clinic? Could we see another trial under-way in this year?
from the other side, page-7
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)